Skip to NavigationSkip to content

digital medicine

US FDA accepts first digital medicine application

Proteus system
The digital medicine includes an ingestible sensor and a wearable patch that monitors drug adherence

The FDA has accepted the first New Drug Application for a digital medicine: Otsuka and Proteus Digital Health’s collaboration of Abilify, embedded with an ingestible sensor.

This is the first time an FDA-approved medication has been submitted for approval combined with a sensor within the medication tablet to measure actual medication-taking patterns and physiologic response.

If approved by the FDA, doctors will be allowed to prescribe Abilify (aripiprazole) tablets with the Proteus ingestible sensor embedded in the tablet.

‘Smart pill’ creator gains new funding

Proteus digital pill

Proteus Digital Health has raised $172 million to help develop its new brand of smart pills that can help patients take their medications correctly and monitor vital signs.

This is the second round of funding that the US health and tech firm has managed to secure and comes after it raised $120 million from the first round of funding in June.

The money, from a number of international backers, will enable the company to advance the manufacturing and commercialisation of its digital medicines, it says in a statement.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches